About one-quarter of adults in the world will experience a stroke in their lifetime.
According to estimates from the Global Burden of Disease Study (GBDS) published online Dec. 20, 2018 in the New England Journal of Medicine.The world has been waiting for a blood test for stroke.
Stroke testing is our top priority.
Strokes are one of the most misdiagnosed medical events in emergency medicine.
Our goal is to develop, manufacture, and commercialize methods of bedside stroke detection that will help clinicians make life changing decisions when minutes and seconds count.
Covid-19
Our testing technology also has the potential to aid in the early detection of severe manifestations of Covid-19.
IP Refinement
Galaxy is committed to working through a board of advisors who are known and trusted experts in the clinical medical field, valued companies with current relationships, marketing channels built through a network of associates, and our own highly experienced management all within an ethical research environment.
Monetizing IP
Success will be drawn from key valued intellectual assets, such as cutting-edge scientific research, licensed patents that have not been monetized, creative manipulation across multiple microbiologic disciplines, and brand development expertise / success.
Medical Breakthroughs for Humanity
Galaxy CCRO was formed by clinicians and scientists who are frustrated by the poor management of stroke. We aim to leverage under-exploited biomarkers and near-patient testing to increase the rate of diagnosis and treatment of ischaemic stroke.
We are focused on serving the human medical needs of today and tomorrow within a morally and ethically sound environment.
Our belief is that our partners in business must hold those same values as dearly as we do to ensure our mission serves mankind with a greater good.